0001209191-17-024746.txt : 20170404
0001209191-17-024746.hdr.sgml : 20170404
20170404161743
ACCESSION NUMBER: 0001209191-17-024746
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170403
FILED AS OF DATE: 20170404
DATE AS OF CHANGE: 20170404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chang David D
CENTRAL INDEX KEY: 0001611024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 17738407
MAIL ADDRESS:
STREET 1: C/O KITE PHARMA, INC.
STREET 2: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-03
0
0001510580
Kite Pharma, Inc.
KITE
0001611024
Chang David D
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
EVP, R&D, Chief Medical Off.
Common Stock
2017-04-03
4
M
0
20000
6.89
A
70165
D
Common Stock
2017-04-03
4
S
0
691
78.53
D
69474
D
Common Stock
2017-04-03
4
S
0
3939
79.63
D
65535
D
Common Stock
2017-04-03
4
S
0
2424
80.44
D
63111
D
Common Stock
2017-04-03
4
S
0
3549
82.00
D
59562
D
Common Stock
2017-04-03
4
S
0
8697
82.60
D
50865
D
Common Stock
2017-04-03
4
S
0
700
83.66
D
50165
D
Employee Stock Option (Right to Buy)
6.89
2017-04-03
4
M
0
20000
0.00
D
2024-06-05
Common Stock
20000
143000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.05 to $78.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.07 to $80.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.07 to $80.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.30 to $82.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.29 to $83.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.42 to $83.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
/s/ David M. Tanen, Attorney-in-Fact
2017-04-04